Abstract
This study aimed to discover to what extent ethical issues are considered in the reimbursement decision process based on health technology assessment (HTA) in Korea, especially for oncology medications. Public summary documents (PSDs) published by the Health Insurance Review and Assessment Service (HIRA) were analyzed for empirical and normative factors. For external comparison, PSDs presented by corresponding institutions of Australia and the United Kingdom were employed. Furthermore, the opinions of eight expert oncologists were obtained regarding the accountability of the evidence in PSDs. Among 7 oncology drugs, there were differences in the final decisions and empirical factors considered, such as selected comparators and interpretation of evidencebetween the PSDs from the three institutions. From an ethical viewpoint, the following matters were deficient in the HTA decision-making process for oncology drugs: clear and reasonable standards; identifying a nd evaluating ethical values; and public accountability for reasonableness about decisions and due process.
| Original language | English |
|---|---|
| Pages (from-to) | 3785-3792 |
| Number of pages | 8 |
| Journal | Asian Pacific Journal of Cancer Prevention |
| Volume | 14 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2013 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Epidemiology
- Oncology
- Public Health, Environmental and Occupational Health
- Cancer Research
Cite this
}
Pitfalls in Reimbursement Decisions for Oncology Drugs in South Korea : Need for Addressing the Ethical Dimensions in Technology Assessment. / Cho, Eun; Park, Euncheol; Kang, Myoung Sheen.
In: Asian Pacific Journal of Cancer Prevention, Vol. 14, No. 6, 01.01.2013, p. 3785-3792.Research output: Contribution to journal › Article
TY - JOUR
T1 - Pitfalls in Reimbursement Decisions for Oncology Drugs in South Korea
T2 - Need for Addressing the Ethical Dimensions in Technology Assessment
AU - Cho, Eun
AU - Park, Euncheol
AU - Kang, Myoung Sheen
PY - 2013/1/1
Y1 - 2013/1/1
N2 - This study aimed to discover to what extent ethical issues are considered in the reimbursement decision process based on health technology assessment (HTA) in Korea, especially for oncology medications. Public summary documents (PSDs) published by the Health Insurance Review and Assessment Service (HIRA) were analyzed for empirical and normative factors. For external comparison, PSDs presented by corresponding institutions of Australia and the United Kingdom were employed. Furthermore, the opinions of eight expert oncologists were obtained regarding the accountability of the evidence in PSDs. Among 7 oncology drugs, there were differences in the final decisions and empirical factors considered, such as selected comparators and interpretation of evidencebetween the PSDs from the three institutions. From an ethical viewpoint, the following matters were deficient in the HTA decision-making process for oncology drugs: clear and reasonable standards; identifying a nd evaluating ethical values; and public accountability for reasonableness about decisions and due process.
AB - This study aimed to discover to what extent ethical issues are considered in the reimbursement decision process based on health technology assessment (HTA) in Korea, especially for oncology medications. Public summary documents (PSDs) published by the Health Insurance Review and Assessment Service (HIRA) were analyzed for empirical and normative factors. For external comparison, PSDs presented by corresponding institutions of Australia and the United Kingdom were employed. Furthermore, the opinions of eight expert oncologists were obtained regarding the accountability of the evidence in PSDs. Among 7 oncology drugs, there were differences in the final decisions and empirical factors considered, such as selected comparators and interpretation of evidencebetween the PSDs from the three institutions. From an ethical viewpoint, the following matters were deficient in the HTA decision-making process for oncology drugs: clear and reasonable standards; identifying a nd evaluating ethical values; and public accountability for reasonableness about decisions and due process.
UR - http://www.scopus.com/inward/record.url?scp=84882725017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882725017&partnerID=8YFLogxK
U2 - 10.7314/APJCP.2013.14.6.3785
DO - 10.7314/APJCP.2013.14.6.3785
M3 - Article
VL - 14
SP - 3785
EP - 3792
JO - Asian Pacific Journal of Cancer Prevention
JF - Asian Pacific Journal of Cancer Prevention
SN - 1513-7368
IS - 6
ER -